Table 1.

Selected assays vs adverse drug reaction relationships from univariate and multivariate analyses with support in the biomedical literature

Assay name	MedDRA name	KW p value	ROC AUC	significant sources a	Literature b
ADRA1A binding	Eosinophilia	3.6E-08	0.85	F	32194050
	Tardive dyskinesia	1.9E-23	0.87	S	45, 46
ADRA2C inhibition	Hallucination, auditory	1.1E-11	0.86	F	33–35
	Paranoia	1.2E-09	0.82	F	33–35
AR binding (agonist)	Erythema nodosum	2.6E-10	0.70	S	27075133
	Ovarian and fallopian tube cysts and neoplasms	2.4E-09	0.70	S	30791431
	Retinal embolism and thrombosis	6.5E-07	0.74	S	29040227
	Ovarian neoplasms malignant 55(excluding germ cell)	5.9E-12	0.82	S	30791431
CHRM1 inhibition	Micturition urgency	4.0E-09	0.73	S	35117285
	Dental caries	3.9E-07	0.73	S	31289718, 12974516
CHRM2 binding	Ileus paralytic	2.7E-10	0.76	S	14607264
DRD2 binding	Breast enlargement	2.4E-08	0.72	S	36–38
	Menstruation irregular	2.4E-08	0.71	S	38
	Salivary hypersecretion	7.9E-11	0.71	S	16421461
DRD3 binding	Tardive dyskinesia	4.3E-31	0.90	F, S	40–42
	Extrapyramidal disorder	5.1E-33	0.87	F, S	19506579
	Gambling disorder	2.8E-09	0.83	S	26192187
	Hyperprolactinemia	1.6E-17	0.86	S	16169407, 33854317
	Blood prolactin increased	4.2E-14	0.88	S	33854317
HRH1 binding	Hypomania	5.0E-17	0.88	S	34572558
HTR2B antagonist	Lethargy	7.4E-07	0.71	S	30666218
	Sleep disorders NEC	1.9E-08	0.72	S	30666218
OPRK1 binding	Salivary hypersecretion	2.8E-08	0.74	S	GOc
PGR agonist	Hyperpigmentation disorders	7.8E-13	0.71	S	39
SLC6A4 binding	Generalized tonic-clonic seizure	1.5E-08	0.76	F	31849820
	Galactorrhea	2.0E-21	0.76	S	14997175
	Blood prolactin increased	2.5E-07	0.78	S	14997175

^a Sources are abbreviated as S (SIDER) and F (FAERS).

^bReferences not discussed in the text are provided as PubMed IDs.

^cEvidence from Gene Ontology.